| Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity TS Fisher, C Kamperschroer, T Oliphant, VA Love, PD Lira, R Doyonnas, ... Cancer Immunology, Immunotherapy 61, 1721-1733, 2012 | 190 | 2012 |
| Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses WR Gould, SM Baxi, R Schroeder, YW Peng, RJ Leadley, JT Peterson, ... Journal of Thrombosis and Haemostasis 3 (4), 733-741, 2005 | 151 | 2005 |
| Impact of project ECHO models of medical tele-education: a systematic review RK McBain, JL Sousa, AJ Rose, SM Baxi, LJ Faherty, C Taplin, A Chappel, ... Journal of General Internal Medicine 34, 2842-2857, 2019 | 123 | 2019 |
| miR-221 promotes tumorigenesis in human triple negative breast cancer cells R Nassirpour, PP Mehta, SM Baxi, MJ Yin PloS one 8 (4), e62170, 2013 | 117 | 2013 |
| Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one … H Cheng, SK Nair, BW Murray, C Almaden, S Bailey, S Baxi, D Behenna, ... Journal of Medicinal Chemistry 59 (5), 2005-2024, 2016 | 96 | 2016 |
| 4-1BB binding molecules B Ahrens, TS Fisher, RM JEROME, K Ladetzki-Baehs, T Oliphant, ... US Patent 8,337,850, 2012 | 84 | 2012 |
| Mindfulness meditation for workplace wellness: An evidence map LG Hilton, NJ Marshall, A Motala, SL Taylor, IM Miake-Lye, S Baxi, ... Work 63 (2), 205-218, 2019 | 67 | 2019 |
| 4-1BB binding molecules B Ahrens, TS Fisher, RM JEROME, K Ladetzki-Baehs, T Oliphant, ... US Patent 8,821,867, 2014 | 63 | 2014 |
| Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design H Cheng, C Li, S Bailey, SM Baxi, L Goulet, L Guo, J Hoffman, Y Jiang, ... ACS Medicinal Chemistry Letters 4 (1), 91-97, 2013 | 62 | 2013 |
| Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 M Walls, SM Baxi, PP Mehta, KKC Liu, JJ Zhu, H Estrella, C Li, M Zientek, ... Clinical Cancer Research 20 (3), 631-643, 2014 | 38 | 2014 |
| Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1) ST Murphy, G Alton, S Bailey, SM Baxi, BJ Burke, TA Chappie, J Ermolieff, ... Journal of medicinal chemistry 54 (24), 8490-8500, 2011 | 38 | 2011 |
| Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90 PP Mehta, P Whalen, SM Baxi, PP Kung, S Yamazaki, MJ Yin Clinical Cancer Research 17 (16), 5432-5442, 2011 | 36 | 2011 |
| Radiation therapy for brain metastases: A systematic review A Garsa, JK Jang, S Baxi, C Chen, O Akinniranye, O Hall, J Larkin, ... Practical radiation oncology 11 (5), 354-365, 2021 | 31 | 2021 |
| Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs RD McBane, RJ Leadley Jr, SM Baxi, K Karnicki, W Wysokinski Arteriosclerosis, thrombosis, and vascular biology 28 (3), 413-418, 2008 | 31 | 2008 |
| Dual functional monoclonal antibody PF-04605412 targets integrin α5β1 and elicits potent antibody-dependent cellular cytotoxicity G Li, L Zhang, E Chen, J Wang, X Jiang, JH Chen, G Wickman, ... Cancer Research 70 (24), 10243-10254, 2010 | 30 | 2010 |
| Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer's treatment J Liu, J Hlávka, D Coulter, SM Baxi, S Mattke, CA Gidengil RAND, 2019 | 26 | 2019 |
| Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro WR Gould, TB McClanahan, KM Welch, SM Baxi, K Saiya‐Cork, L Chi, ... Journal of Thrombosis and Haemostasis 4 (4), 834-841, 2006 | 24 | 2006 |
| A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications SM Baxi, R Beall, J Yang, TK Mackey Globalization and Health 15, 1-14, 2019 | 23 | 2019 |
| Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells SM Baxi, W Tan, ST Murphy, T Smeal, MJ Yin PLoS One 7 (10), e48402, 2012 | 21 | 2012 |
| Targeting the mTOR pathway in tumor malignancy H Cheng, M Walls, S M Baxi, MJ Yin Current cancer drug targets 13 (3), 267-277, 2013 | 20 | 2013 |
